The product is used in the treatment of breast cancer and advanced gastric cancer. Breast cancer has become the most diagnosed cancer in Mexico, overtaking prostate and colorectal cancers, the company added. Developed in-house by the research team at the Zydus Research Centre (ZRC), the Trastuzumab biosimilar was launched in 2016 in India under the brand name Vivitra. Since then, an estimated 1 lakh patients have been treated with the therapy, the company added.
